Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Retina Consultants of Texas

Neither a doctor nor a teaching hospital

Research payments

$59,677,844

6,709 payments

Through program year 2025, Retina Consultants of Texas is reported as receiving $59,677,844 in research payments, across 6,709 payments.

By program year

6 rows
Year Kind Amount Payments
2025 Research $34,107,449 4,976
2024 Research $21,142,263 1,266
2023 Research $1,790,005 299
2022 Research $1,164,863 110
2021 Research $1,473,236 57
2020 Research $28 1

Breakdown

Who paid Research payments · program years 2020–2025
  1. Novartis Pharmaceuticals Corporation $45,419,488 36 payments
  2. Regeneron Pharmaceuticals, Inc. $8,980,659 5,352 payments
  3. Bayer HealthCare Pharmaceuticals Inc. $2,492,620 1,056 payments
  4. Alexion Pharmaceuticals, Inc. $1,736,856 12 payments
  5. Kyowa Kirin, Inc. $358,160 144 payments
  6. Ocular Therapeutix, Inc. $167,652 31 payments
  7. Neurotech Pharmaceuticals, Inc. $132,657 14 payments
  8. Boehringer Ingelheim International GmbH $96,541 9 payments
  9. EyePoint Pharmaceuticals US, Inc. $96,217 6 payments
  10. Takeda Pharmaceuticals U.S.A., Inc. $65,606 1 payment
Studies the money was for Research payments · program years 2020–2025
  1. A Randomized, Participant and Investigator Masked, Placebo-Controlled, Multicenter, Proof-Of-Concept Study to Assess the Safety and Efficacy of Lnp023 (Iptacopan) in Patients With Early and Intermediate Age-Related MacUlar Degeneration $44,037,994 8 payments
  2. A Phase 3b Single-Arm Study of Aflibercept 8 mg in Participants With Neovascular Age-Related Macular Degeneration (nAMD) or Diabetic Macular Edema (DME) $7,259,845 4,389 payments
  3. A Phase 2, Double Masked, Placebo Controlled, Dose Range Finding Study of Danicopan (ALXN2040) in Patients with Geographic Atrophy (GA) Secondary to Age Related Macular Degeneration (AMD) $1,736,856 12 payments
  4. BAY 865321, Aflibercept 8mg in RVO $1,316,206 691 payments
  5. A Randomized, Double-Masked, Active-Controlled Phase 2/3 Study of the Efficacy and Safety of High-Dose Aflibercept in Patients With Diabetic Macular Edema $944,246 574 payments
  6. A Multicenter Randomized Double Masked Phase 3A Study to Assess Safety and Efficacy of Brolucizumab 6 MG Q4 Weeks Compared to Aflibercept 2 MG Q4 Weeks in Patients With Neovascular Age Related MacUlar Degeneration Namd With Persistent Retinal Fluid $642,973 1 payment
  7. BAY865321, HD 8mg, AMD - Ph 3 $569,086 93 payments
  8. A 96-Week, Two-Arm, Randomized, Single-Masked, Multi-Center, Phase III Study Assessing the Efficacy and Safety of Brolucizumab 6 MG Compared to Panretinal Photocoagulation Laser in Patients With Proliferative Diabetic Retinopathy $487,173 9 payments
  9. BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of High Dose Aflibercept in Patients With Neovascular Age-Related Macular Degeneration $351,490 100 payments
  10. A Study in Patients With Diabetic Macular Edema or Neovascular Age-Related Macular Degeneration to Evaluate a High Dose Aflibercept (8 mg) Prefilled Syringe $272,468 137 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record